Last updated: September 3, 2026
Eplontersen sodium, marketed as Wainua by AstraZeneca, is a monthly subcutaneous antisense drug for hereditary transthyretin-mediated amyloidosis with polyneuropathy. The U.S. launch began in early 2024 after FDA approval in December 2023. Its commercial outlook depends on four factors: competition from vutrisiran and inotersen, expansion into transthyretin amyloid cardiomyopathy, payer acceptance of a high-cost chronic therapy, and AstraZeneca’s ability to convert patients from older RNA-targeted treatments.
Wainua has a differentiated delivery profile. It is administered once monthly through a prefilled autoinjector and is designed to reduce hepatic transthyretin production. The principal commercial limitation is that its initial U.S. label covers a smaller hereditary transthyretin amyloidosis population with polyneuropathy rather than the larger cardiomyopathy market.
Standalone revenue disclosure remains limited. AstraZeneca reports Wainua sales within its rare-disease portfolio, while Ionis Pharmaceuticals receives development, commercial and royalty economics under its collaboration agreement. Public filings do not provide enough detail to construct a fully reliable product-level earnings forecast beyond company-reported sales data.
What is eplontersen sodium and how does Wainua work?
Eplontersen is a ligand-conjugated antisense oligonucleotide targeting transthyretin messenger RNA. It binds to TTR mRNA in hepatocytes and promotes its degradation, reducing production of both wild-type and variant transthyretin protein.
The drug uses Ionis Pharmaceuticals’ ligand-conjugated antisense technology. A ligand facilitates liver uptake, allowing lower and less frequent dosing than earlier antisense products. Wainua is administered as a 45 mg subcutaneous injection once every four weeks through a prefilled autoinjector.
| Attribute |
Wainua |
| Active ingredient |
Eplontersen sodium |
| Sponsor |
AstraZeneca |
| Originator technology |
Ionis Pharmaceuticals |
| FDA application |
NDA 217806 |
| Initial approval |
December 21, 2023 |
| Initial indication |
Polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults |
| Administration |
45 mg subcutaneous injection every four weeks |
| Delivery system |
Prefilled autoinjector |
| Therapeutic class |
Antisense oligonucleotide |
| Target |
Transthyretin mRNA |
| Commercial territory |
AstraZeneca-led global commercialization under collaboration arrangements |
The FDA approval was based primarily on the NEURO-TTRansform study, which demonstrated preservation of neurologic function and reduced decline in quality-of-life measures relative to an external placebo group. The study also showed substantial reductions in serum transthyretin levels. [1]
What is the FDA regulatory status of eplontersen?
Wainua has full U.S. approval for adults with polyneuropathy caused by hereditary transthyretin-mediated amyloidosis. The label does not initially include transthyretin-mediated cardiomyopathy.
The FDA approval places Wainua in a commercially valuable but relatively narrow orphan-disease segment. Hereditary transthyretin amyloidosis is rare, genetically heterogeneous and frequently underdiagnosed. The treatable population is concentrated in specialist neurology, cardiology, genetics and amyloidosis centers.
The main regulatory opportunity is label expansion into cardiomyopathy. AstraZeneca has been evaluating eplontersen in the CARDIO-TTRansform study. A successful cardiomyopathy indication would materially expand the addressable population and allow Wainua to compete directly with vutrisiran, which has a broader U.S. label following its cardiomyopathy approval.
What regulatory milestones matter commercially?
| Milestone |
Commercial implication |
| U.S. polyneuropathy approval in December 2023 |
Enabled initial U.S. launch |
| Monthly autoinjector availability |
Supports home administration and reduces infusion-center dependence |
| Cardiomyopathy clinical development |
Determines whether Wainua can address the larger ATTR-CM market |
| International approvals |
Expand volume but introduce country-level pricing and reimbursement pressure |
| Long-term safety and outcome data |
Affect payer confidence and specialist prescribing |
The absence of an initial cardiomyopathy indication limits early revenue. ATTR-CM is the larger commercial opportunity because it includes patients whose primary disease burden is cardiac rather than neurologic.
How large is the eplontersen market opportunity?
The market is divided between hereditary transthyretin amyloidosis with polyneuropathy, hereditary transthyretin amyloidosis with cardiomyopathy and wild-type transthyretin amyloid cardiomyopathy.
Wainua’s initial label reaches the first group only. The addressable population is therefore smaller than the total ATTR treatment market, but the disease has high treatment intensity, specialist concentration and substantial unmet need.
The commercial market is shaped by several factors:
- Genetic testing and earlier diagnosis increase the identified patient pool.
- Improved survival creates a larger treated population over time.
- Monthly home administration may improve persistence.
- Competing RNA silencers provide alternatives with different dosing schedules.
- Payers may require treatment sequencing or diagnostic confirmation.
- Cardiomyopathy expansion would multiply the eligible population.
AstraZeneca’s acquisition of Alexion gave it an established rare-disease infrastructure, specialist relationships and payer capabilities. That infrastructure reduces launch risk compared with a standalone biotechnology commercialization model.
How does Wainua compare with Amvuttra and Tegsedi?
Wainua competes mainly with Alnylam Pharmaceuticals’ Amvuttra and Ionis’ older antisense drug Tegsedi.
| Product |
Active ingredient |
Company |
Delivery |
Initial commercial position |
| Wainua |
Eplontersen |
AstraZeneca/Ionis |
Monthly subcutaneous autoinjector |
Polyneuropathy |
| Amvuttra |
Vutrisiran |
Alnylam |
Subcutaneous injection every three months |
Polyneuropathy and cardiomyopathy |
| Tegsedi |
Inotersen |
Ionis/AstraZeneca |
Subcutaneous injection, generally weekly |
Polyneuropathy |
| Onpattro |
Patisiran |
Alnylam |
Intravenous infusion every three weeks |
Polyneuropathy and cardiomyopathy |
Amvuttra has the strongest current dosing advantage because quarterly administration is less frequent than Wainua’s monthly schedule. Wainua counters with an autoinjector that can support home treatment, while Amvuttra is commonly administered by a healthcare professional depending on the market and treatment setting.
Tegsedi is disadvantaged by weekly dosing and older-generation delivery characteristics. Wainua is positioned as a replacement or upgrade option for some patients receiving Tegsedi, although Ionis and AstraZeneca must manage internal portfolio cannibalization.
Vutrisiran’s cardiomyopathy indication gives Alnylam a broader commercial platform. Eplontersen’s financial trajectory will therefore depend heavily on whether it obtains a comparable indication and whether its monthly home-use format produces better persistence or patient preference.
What is the pricing and reimbursement outlook for Wainua?
Wainua is priced as a high-cost orphan drug. Publicly reported U.S. wholesale acquisition pricing has been approximately $6,800 to $7,000 per monthly dose, implying an annual list-price level near $82,000 to $84,000 before discounts and rebates.
Actual net price is lower because of commercial rebates, government discounts, patient assistance and negotiated payer contracts. The economic value proposition rests on avoiding progression of irreversible neuropathy, reducing treatment burden and potentially delaying disability-related costs.
Payers are likely to impose several controls:
- Confirmed hereditary TTR mutation
- Specialist diagnosis
- Documentation of polyneuropathy
- Prior authorization
- Coverage criteria based on disease stage
- Possible sequencing against vutrisiran or inotersen
- Reauthorization based on clinical stability
The high list price does not automatically translate into high revenue. The critical variables are treated-patient growth, persistence, reimbursement approval and the rate of discounts required to compete with Amvuttra.
What are the financial prospects for eplontersen?
Wainua entered the market with a high-value orphan-drug profile but a narrow initial label. The financial trajectory is likely to follow four phases.
Launch phase: 2024 to 2025
The first phase is characterized by limited revenue, physician education, diagnostic expansion and payer contracting. Sales are likely to build gradually because hereditary ATTR patients are treated through a concentrated specialist network and many diagnosed patients already receive competing therapies.
AstraZeneca’s financial reporting does not provide enough product-level detail to isolate all Wainua economics from broader rare-disease performance. Ionis separately reports collaboration revenue and royalties, but those figures may combine multiple commercial arrangements and milestone categories.
Expansion phase: 2025 to 2027
Revenue growth depends on conversion from Tegsedi, new diagnosis, international reimbursement and the cardiomyopathy program. The strongest upside case requires a successful cardiomyopathy label and rapid adoption in both hereditary and wild-type ATTR-CM.
Without cardiomyopathy approval, Wainua remains a focused polyneuropathy product. Its annual revenue ceiling would be constrained by the size of that population and Amvuttra’s established position.
Scale phase: 2027 onward
If eplontersen obtains broader labeling, AstraZeneca can leverage one product across a larger ATTR franchise. The monthly autoinjector could support home-treatment economics and reduce administration costs relative to intravenous therapy.
Longer-term revenue is exposed to price pressure. Rare-disease payers increasingly use outcomes evidence, competitive contracting and indication-specific management. A broader label would raise volume but could also increase rebates as Wainua competes directly against Amvuttra.
Financial drivers
| Driver |
Effect on Wainua |
| Cardiomyopathy approval |
Very high positive impact |
| U.S. patient conversion |
High positive impact |
| Monthly autoinjector adoption |
Positive impact on persistence and convenience |
| Amvuttra quarterly dosing |
Negative competitive pressure |
| Payer restrictions |
Negative impact on access and net price |
| International launches |
Positive volume, lower average net price |
| Manufacturing scale |
Positive margin impact over time |
| Safety or tolerability concerns |
Negative impact on uptake |
What licensing deal governs eplontersen economics?
AstraZeneca and Ionis entered into a strategic collaboration covering eplontersen, formerly known as IONIS-TTR-LRx. The agreement included an upfront payment, development and regulatory milestones, commercial milestones and tiered royalties.
AstraZeneca assumed primary responsibility for development and commercialization in the collaboration territories. Ionis retained economic participation through royalties and other contractual payments. The arrangement gives AstraZeneca control over launch strategy while allowing Ionis to monetize its antisense platform without funding the full global commercial infrastructure.
The deal is commercially important because it aligns the parties around label expansion. AstraZeneca has the resources to pursue cardiomyopathy development, while Ionis benefits from volume growth without bearing the full cost of manufacturing, sales and marketing.
What patents protect eplontersen sodium?
Eplontersen is protected through a layered intellectual-property estate rather than a single composition-of-matter patent. Relevant categories include:
- Antisense sequences targeting transthyretin
- Ligand-conjugated oligonucleotide structures
- Chemical modifications and backbone chemistry
- Pharmaceutical compositions
- Dosing regimens
- Methods for treating hereditary ATTR and related disorders
- Manufacturing and purification processes
The exact enforceable term depends on the claims, priority dates, patent-term adjustment, patent-term extension and jurisdiction. Public regulatory and company materials do not establish one definitive global expiration date for the complete Wainua estate.
Is Wainua listed in the Orange Book?
Wainua is approved under NDA 217806. The FDA Orange Book is the controlling source for any listed patents and regulatory exclusivity associated with the NDA. Orphan-drug exclusivity applies to the approved indication for seven years from approval under the Orphan Drug Act, subject to statutory exceptions.
The initial U.S. orphan exclusivity period is therefore expected to extend into December 2030. That exclusivity protects the approved indication, not every possible use of eplontersen.
A generic or follow-on entrant would face additional barriers because eplontersen is an antisense oligonucleotide rather than a conventional small molecule. Regulatory standards for demonstrating pharmaceutical equivalence, analytical comparability and clinical substitutability may be more complex than for ordinary tablet products.
What generic entry risks exist for Wainua?
Near-term generic erosion risk is low. The main barriers are:
- Orphan-drug exclusivity through approximately 2030 for the original indication
- Complex oligonucleotide characterization
- Proprietary ligand-conjugation technology
- Patent claims covering sequences, chemistry and use
- Limited commercial incentive for a small rare-disease population
- Specialist prescribing and diagnostic requirements
- Manufacturing know-how and quality-control requirements
The more immediate risk is therapeutic substitution rather than generic entry. Alnylam’s Amvuttra can capture patients through quarterly dosing and its broader cardiomyopathy label. Wainua’s own commercial success may also reduce Tegsedi revenue within the Ionis-AstraZeneca portfolio.
Which companies are challenging Wainua commercially?
Alnylam is the primary competitive threat. Its commercial advantages include:
- Earlier market presence
- Established ATTR physician relationships
- Vutrisiran’s quarterly dosing
- Cardiomyopathy labeling
- Existing patient and reimbursement infrastructure
Ionis and AstraZeneca retain countervailing advantages:
- Monthly home administration
- A newer ligand-conjugated antisense design
- AstraZeneca’s rare-disease commercial platform
- Potential conversion from Tegsedi
- A clinical-development pathway into cardiomyopathy
Pfizer’s tafamidis remains a major disease-modifying competitor in ATTR cardiomyopathy, although it operates through a different mechanism and is not a direct substitute for polyneuropathy treatment. Its presence raises the competitive threshold for any eplontersen cardiomyopathy launch.
How strong is the commercial and patent estate for eplontersen?
The commercial estate is strong in technology and infrastructure but incomplete in label breadth. AstraZeneca has the resources to support a global rare-disease launch, and Ionis provides established antisense expertise. The initial indication, however, does not reach the largest ATTR segment.
The patent estate likely provides meaningful protection across oligonucleotide design, conjugation, dosing and therapeutic use. Its practical strength will depend on claim scope, validity, Orange Book listings and the ability to enforce patents against complex follow-on products.
Wainua’s overall investment profile is therefore asymmetric:
- High upside if cardiomyopathy development succeeds
- Moderate near-term revenue from the polyneuropathy launch
- Low immediate generic risk
- High competitive risk from Amvuttra
- Meaningful royalty value for Ionis
- Significant dependence on payer access and patient diagnosis
Key Takeaways
- Eplontersen sodium is marketed in the U.S. as Wainua by AstraZeneca.
- FDA approval occurred on December 21, 2023, for hereditary ATTR polyneuropathy in adults.
- The drug is administered monthly through a prefilled autoinjector.
- Its largest commercial opportunity is expansion into transthyretin amyloid cardiomyopathy.
- Amvuttra is the leading direct competitive threat because of quarterly dosing and broader labeling.
- Wainua has low near-term generic risk due to orphan exclusivity, complex oligonucleotide manufacturing and layered IP.
- Product-level revenue forecasting is constrained by limited standalone disclosure from AstraZeneca and Ionis.
- Ionis benefits through collaboration payments and royalties while AstraZeneca funds commercialization and development.
- The principal financial catalyst is a successful cardiomyopathy indication.
- The principal downside risk is slow patient conversion in a market already served by Amvuttra and other transthyretin-directed therapies.
FAQs About Eplontersen Sodium
When did Wainua launch in the United States?
Wainua launched in the United States in early 2024 after FDA approval in December 2023.
Is eplontersen the same as inotersen?
No. Eplontersen and inotersen are both Ionis-origin antisense medicines targeting transthyretin, but eplontersen uses ligand-conjugated chemistry and monthly dosing, while inotersen generally requires weekly administration.
Can Wainua treat wild-type transthyretin amyloidosis?
The initial U.S. approval is for hereditary ATTR polyneuropathy. It does not establish an approved indication for wild-type ATTR cardiomyopathy.
What is the main threat to Wainua sales?
The main threat is Amvuttra, or vutrisiran, because it offers quarterly dosing and has a broader ATTR indication that includes cardiomyopathy.
Does eplontersen have biosimilar risk?
Traditional biosimilar risk is limited because eplontersen is an antisense oligonucleotide rather than a biologic protein. The more relevant long-term risk is a complex generic or follow-on oligonucleotide product supported by regulatory comparability and patent challenges.
References
- U.S. Food and Drug Administration. (2023, December 21). FDA approves drug to treat hereditary transthyretin-mediated amyloidosis. https://www.fda.gov
- U.S. Food and Drug Administration. (2023). Wainua prescribing information. AstraZeneca Pharmaceuticals LP. https://www.accessdata.fda.gov
- AstraZeneca. (2024). Annual report and Form 20-F 2023. https://www.astrazeneca.com/investor-relations/annual-reports.html
- Ionis Pharmaceuticals, Inc. (2024). Annual report on Form 10-K for the year ended December 31, 2023. https://ir.ionispharma.com
- Ionis Pharmaceuticals, Inc., & AstraZeneca. (2019, November 14). Ionis and AstraZeneca enter strategic collaboration for IONIS-TTR-LRx. https://ir.ionispharma.com
- AstraZeneca. (2024). Wainua approved in the US for adults with hereditary transthyretin-mediated amyloidosis with polyneuropathy. https://www.astrazeneca.com/media-centre.html
- Alnylam Pharmaceuticals, Inc. (2022). Amvuttra prescribing information. https://www.accessdata.fda.gov
- Adams, D., Gonzalez-Duarte, A., O'Riordan, W. D., et al. (2018). Patisiran, an RNAi therapeutic, for hereditary transthyretin-mediated amyloidosis. New England Journal of Medicine, 379(1), 11-21. https://doi.org/10.1056/NEJMoa1716153
